Research statistics
Setmelanotide research: publications and trials
At a glance
Publications, all years
129
Since 2009
Publications in 2026 so far
30
Through November 15, 2026
Human clinical research
35.7%
46 of 129 classified
Registered clinical trials
26
ClinicalTrials.gov
Randomized controlled trials
5
Publications reporting an RCT in people
Systematic reviews and meta-analyses
2
Preclinical studies
24.0%
19 animal · 9 in vitro · 3 computational
Records that only mention it
87
Not counted above
Status in the library: FDA-approved. Groups: Melanocortin agonists.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Setmelanotide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2009 | 0 | 1 | 0 | 0 | 1 |
| 2012 | 0 | 1 | 0 | 0 | 1 |
| 2015 | 1 | 1 | 0 | 0 | 2 |
| 2016 | 1 | 1 | 1 | 0 | 3 |
| 2017 | 1 | 0 | 0 | 0 | 1 |
| 2018 | 2 | 1 | 1 | 0 | 4 |
| 2019 | 0 | 1 | 2 | 0 | 3 |
| 2020 | 4 | 0 | 2 | 1 | 7 |
| 2021 | 2 | 6 | 6 | 1 | 15 |
| 2022 | 4 | 3 | 4 | 1 | 12 |
| 2023 | 4 | 2 | 10 | 0 | 16 |
| 2024 | 6 | 4 | 8 | 2 | 20 |
| 2025 | 7 | 2 | 4 | 1 | 14 |
| 2026 (to date) | 14 | 8 | 4 | 4 | 30 |
Study types
| Review | 40 |
|---|---|
| Animal study | 19 |
| Other clinical trial | 17 |
| Case report | 16 |
| In vitro study | 9 |
| Editorial, letter or other | 9 |
| Observational human study | 8 |
| Randomized controlled trial | 5 |
| Computational study | 3 |
| Guideline or consensus | 1 |
| Meta-analysis | 1 |
| Systematic review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Obesity and weight management | 95 |
|---|---|
| Metabolic health | 35 |
| Neurological and mental health | 35 |
| Endocrinology | 22 |
| Dermatology | 5 |
| Cardiovascular | 4 |
| Immune system | 4 |
| Antimicrobial and infectious disease | 2 |
| Cognitive health | 2 |
| Oncology | 2 |
| Gastrointestinal | 1 |
| Longevity and aging | 1 |
Registered clinical trials
3 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 19 · Active, not recruiting: 2 · Recruiting: 2 · Approved for marketing: 1 · Enrolling by invitation: 1 · Unknown status: 1
Phase not applicable: 1 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 9 · Phase 2 / Phase 3: 1 · Phase 3: 9 · Phase 4: 2
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.
Expert opinion on drug safety · February 12, 2025 · Meta-analysis · cited 3 times
PMID 39924461 · DOI 10.1080/14740338.2025.2465880 · Reviews and meta-analyses
- A systematic literature review of economic evaluations of setmelanotide.
European journal of clinical pharmacology · April 20, 2026 · Systematic review · cited 0 times
PMID 42008191 · DOI 10.1007/s00228-026-04058-y · Reviews and meta-analyses
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine · July 1, 2026 · Randomized controlled trial · cited 12 times · open access
PMID 42418774 · DOI 10.1056/nejmoa2512275 · Human clinical research
- Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism · September 1, 2025 · Randomized controlled trial · cited 11 times · open access
PMID 39919037 · DOI 10.1210/clinem/dgaf079 · Human clinical research
- Could setmelanotide be the game-changer for acquired hypothalamic obesity?
Frontiers in endocrinology · January 4, 2024 · Randomized controlled trial · cited 22 times · open access
PMID 38239988 · DOI 10.3389/fendo.2023.1307889 · Human clinical research
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
The lancet. Diabetes & endocrinology · November 7, 2022 · Randomized controlled trial · cited 205 times · open access
PMID 36356613 · DOI 10.1016/s2213-8587(22)00277-7 · Human clinical research
- RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
The Journal of clinical endocrinology and metabolism · February 12, 2015 · Randomized controlled trial · cited 174 times · open access
PMID 25675384 · DOI 10.1210/jc.2014-4024 · Human clinical research
- Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.
The Journal of clinical endocrinology and metabolism · October 19, 2026 · Other clinical trial · cited 0 times
PMID 42895739 · DOI 10.1210/clinem/dgag345 · Human clinical research
- Quality of life improvements with setmelanotide treatment in acquired hypothalamic obesity: TRANSCEND trial interview results from US participants.
Frontiers in behavioral neuroscience · July 15, 2026 · Other clinical trial · cited 0 times · open access
PMID 42528856 · DOI 10.3389/fnbeh.2026.1830070 · Human clinical research
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.) · February 17, 2026 · Other clinical trial · cited 2 times · open access
PMID 41703984 · DOI 10.1002/oby.70125 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
The lancet. Diabetes & endocrinology · October 30, 2020 · Other clinical trial · cited 487 times · open access
PMID 33137293 · DOI 10.1016/s2213-8587(20)30364-8 · Human clinical research
- Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
The New England journal of medicine · July 1, 2016 · Other clinical trial · cited 482 times
PMID 27468060 · DOI 10.1056/nejmoa1512693 · Human clinical research
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.
EClinicalMedicine · March 20, 2023 · Review · cited 457 times · open access
PMID 36992862 · DOI 10.1016/j.eclinm.2023.101882 · Reviews and meta-analyses
- MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Nature medicine · May 7, 2018 · Other clinical trial · cited 309 times
PMID 29736023 · DOI 10.1038/s41591-018-0015-9 · Human clinical research
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Molecular metabolism · July 8, 2017 · Other clinical trial · cited 302 times · open access
PMID 29031731 · DOI 10.1016/j.molmet.2017.06.015 · Human clinical research
Latest publications
- Early nutrition impacts later setmelanotide treatment of obesity in mice.
JCI insight · November 9, 2026 · Animal study · cited 0 times · open access
PMID 43001579 · DOI 10.1172/jci.insight.197382 · Animal studies
- Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.
The Journal of clinical endocrinology and metabolism · October 19, 2026 · Other clinical trial · cited 0 times
PMID 42895739 · DOI 10.1210/clinem/dgag345 · Human clinical research
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42874119 · DOI 10.1056/nejmc2610994 · Commentary and other
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42874120 · DOI 10.1056/nejmc2610994 · Commentary and other
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.
The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42874121 · DOI 10.1056/nejmc2610994 · Commentary and other
- Sequential Liraglutide and Setmelanotide Therapy in Bardet-Biedl Syndrome: Metabolic and Renal Outcomes in a Real-World Case Report and Literature Review.
Nephron · September 15, 2026 · Case report · cited 0 times
PMID 42743093 · DOI 10.1159/nef/adtag006 · Human clinical research
- Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet-Biedl Syndrome.
International journal of molecular sciences · August 29, 2026 · Case report · cited 1 times · open access
PMID 42737637 · DOI 10.3390/ijms27177740 · Human clinical research
- Setmelanotide
August 15, 2026 · Review · cited 0 times · open access
PMID 42672527 · Reviews and meta-analyses
- Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
Journal of medicinal chemistry · August 1, 2026 · Animal study · cited 0 times
PMID 42611594 · DOI 10.1021/acs.jmedchem.6c01457 · Animal studies
- Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.
The Journal of clinical endocrinology and metabolism · August 1, 2026 · Observational human study · cited 1 times · open access
PMID 42538728 · DOI 10.1210/clinem/dgag293 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Imcivree; RM-493; Setmelanotida; Setmelanotide; Setmelanotidum
((TITLE_ABS:"Imcivree" OR CHEM:"Imcivree") OR (TITLE_ABS:"RM-493" OR CHEM:"RM-493" OR TITLE_ABS:"RM493" OR CHEM:"RM493") OR (TITLE_ABS:"Setmelanotida" OR CHEM:"Setmelanotida") OR (TITLE_ABS:"Setmelanotide" OR CHEM:"Setmelanotide") OR (TITLE_ABS:"Setmelanotidum" OR CHEM:"Setmelanotidum")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Setmelanotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/setmelanotide